The cell cycle regulatory enzyme, cdk (cyclin-dependent kinase) 2 kinase, is activated in the rat carotid artery after balloon angioplasty injury, and may mediate smooth muscle proliferation. To 
Introduction
Neointimal hyperplasia after balloon injury results from vascular smooth muscle. cell migration and proliferation (1) (2) (3) . Many growth factors, including thrombin, fibroblast growth factor, and PDGF, mediate neointima formation by activating cell cycle progression (4) (5) (6) (7) . Since cyclin was first discovered, it has become clear that cell growth is dependent on the coordinated actions of cell cycle regulatory genes (8, 9) . Recent reports that the transcription factor, E2F, forms a complex with cyclin A and cdk (cyclin-dependent kinase) 2 kinase reveal that activation and phosphorylation of these cell cycle regulatory genes are critical to the process ofcell growth and proliferation (10) (11) (12) . Previously, we observed an increased gene expression of cell division cycle (cdc) 2 kinase in injured rat carotid arteries ( 13) . The enzyme cdk 2 kinase, cloned as a homologue of cdc 2 kinase (14) , plays an important role in transition through the GI1s phase, whereas cdc 2 kinase is important in the G2,M phase. Recent progress in the study of cell cycle progression regulation has reinforced the pivotal importance of the GI1s phase in the process of cell proliferation ( 15, 16) . Therefore, we hypothesize that cdk 2 kinase may play a critical role in neointima formation. Using antisense phosphorothioate oligodeoxynucleotides (ODN) I against cdk 2 kinase, this study tests the hypothesis that inhibition of the expression ofthis key enzyme can inhibit neointimal hyperplasia after balloon injury of the rat carotid artery.
The antisense method is an innovative and attractive strategy to block the transcription or translation of specific genes. Modifications ofthe ODN backbone such as phosphorothioate have resulted in increased resistance to nucleases. Using the modified ODN, Simons et al. ( 17) have recently reported that antisense ODN directed against c-myb inhibited neointima formation when administrated at high doses (200 ag/vessel) via a periadventitial pluronic gel delivery system. However, this peri-adventitial delivery method is impractical for the purpose ofpreventing restenosis after percutaneous transluminal angioplasty. We have therefore developed an intraluminal antisense ODN delivery system as a more efficient therapeutic strategy. To increase efficiency ofcellular uptake ofODN, we have developed a highly effective hemagglutinating virus of Japan (HVJ)-liposome method that enhances uptake of ODN packaged in liposomes coated with inactivated HVJ (18) (19) (20) (21) (22) (23) . HVJ promotes fusion of the liposome with vascular cells and delivers the ODN intracellularly (23) . Using this molecular delivery system, this study shows that a single intraluminal administration of antisense cdk 2 kinase ODN resulted in sustained ODN stability within the vessel wall and prevented neointima formation after balloon injury in rat carotid artery model. Methods Synthesis of oligonucleotides and selection of sequence targets. The sequences ofODN against human cdk 2 kinase used in this study were: antisense, 5'-GAA-GTT-CTC-CAT-GAA-GCG-3'; sense, 5'-CGC-TTC-ATG-GAG-AAC-TTC-3'(-6 to +12 of human sequence; these  sequences are not different between mouse and human cdk 2 kinase) . This antisense ODN specifically inhibits cdk 2 kinase protein synthesis and serum-stimulated growth in rat VSMC (our unpublished observation). We also synthesized sense and antisense cdc 2 kinase ODN (antisense, 5'-GTC-TTC-CAT-AGT-TAC-TCA-3'; sense, 5'-TGA-GTA-ACT-ATG-GAA-GAC-3'; -9 to +9 of mouse sequence) (24) . Scrambled ODN (5'-CTT-CGT-CGG-TAC-CGT-CTT-C-3'), a 4-bp missense of the cdc 2 kinase antisense ODN (5'-GTCTGCCGT-CGTTAGTCA-3'), and antisense thrombomodulin (5'-ACC-CAG-AAA-GAA-AAT-CCC-3') were used as additional negative controls. Synthetic ODN were purified over a NAP 10 column (Pharmacia Fine Chemicals, Piscataway, NJ) and quantitated by spectrophotometry (25) .
Preparation ofHVJ-liposomes. Phosphatidylserine, phosphatidylcholine, and cholesterol were mixed in a weight ratio of 1:4:8:2 (19) (20) (21) (22) (23) . Dried lipid was hydrated in 200,Ml of balanced salt solution (BSS: 137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl, pH 7.6) containing sense or antisense ODN. The control group did not contain ODN (200 yd BSS). Liposomes were prepared by shaking and sonication. Purified HVJ (Z strain) was inactivated by UV irradiation ( 1 10 erg/mm2 per s) for 3 min just before use. The liposome suspension (0.5 ml, containing 10 mg of lipids) was mixed with HVJ ( 10,000 hemagglutinating units) in a total volume of 4 ml BSS. The mixture was incubated at 4°C for 5 min and then for 30 min with gently shaking at 37°C. Free HVJ was removed from the HVJ-liposomes by sucrose density gradient centrifugation. In this study, the preparation ofHVJ complex was optimized to achieve the maximum effect of antisense ODN in VSMC (data not shown).
In vivo gene transfer. A 2 French Fogarty catheter was used to induce vascular injury in male Sprague-Dawley rats (400-500 g; Charles River Labs., Wilmington, MA) ( 13) . These rats were anesthetized with ketamine, and the left common carotid artery was surgically exposed. A cannula was introduced into the common carotid via the external carotid artery. In vivo gene transfer was performed under the following condition: vascular injury of the common carotid was induced by the passage and inflation of a balloon catheter through an arteriotomy in the external carotid artery three times. The injured segment was transiently isolated by temporary ligatures. The HVJ-liposome complex, liposome complex without HVJ particles, or ODN alone was infused into the segment and incubated for 10 min at room temperature. After a 10-min incubation, the infusion cannula was removed. After the transfection, blood flow to the common carotid was restored by release ofthe ligatures, and the wound was then closed. No adverse neurological or vascular effects were observed in any animal undergoing this procedure.
Reverse (Fig. 2) . ODN treatment did not alter the medial area (Fig. 2) . The reduction in neointima formation was limited to transfected regions (neointimal/medial areas ratio: transfected region = 0.597±0.131 vs. untransfected region = 1.156±0.079; P < 0.01 ). To investigate the contribution of HVJ transfer to the effect ofODN in vivo, we compared the biological action of antisense cdk 2 ODN using the direct transfer, liposome-mediated transfer without the HVJ particle, and the HVJ-liposome method. Neither direct passive transfer at 10-fold higher concentrations (150 ,uM) nor liposome-mediated transfer without the HVJ particle ( 15 ,uM) had any inhibitory effect on the neointimal lesion (Fig. 3) .
It is noteworthy that antisense cdk 2 kinase ODN did not completely suppress neointima formation. We have observed that cdc 2 kinase mRNA is also induced after vascular injury ( 13) . Given the coordinated interaction of cdc 2 and cdk 2 kinase in the regulation ofcell cycle progression, we postulated that concomitant inhibition ofboth factors would be the most effective therapeutic strategy. Indeed, the combination of antisense cdc 2 and cdk 2 kinase ODN showed further inhibition of neointima formation (85%) as compared with either antisense cdc 2 or cdk 2 kinase ODN alone (Fig. 4) (Fig. 5 A) . However (Fig. 5 B) 
Discussion
One of the important diseases potentially amendable to antisense gene therapy is restenosis after angioplasty, since the long-term effectiveness ofthis procedure is limited by the development of restenosis in > 40% of patients (27) (28) (29) . Neointima formation after angioplasty involves a complex interaction between multiple growth factors that promote vascular smooth muscle cell proliferation and migration ( 1-7) . Therefore, it appears unlikely that selective inhibition ofa particular growth factor will completely prevent lesion formation. Growth factor-induced cell proliferation involves the sequential activation of intracellular proteins that promote cell cycle progression. Accordingly, we hypothesize that restenosis could be prevented by the blockade of genes regulating cell cycle progression, the final common pathway. In this study we focused on cdk 2 kinase (a serine-threonine protein kinase), which interacts to form a complex with cyclin A or other cyclins that is essential for cell cycle progression regulation ( 10-12, 15, 16 , c-myc, c-myb) ( 10-12) . We therefore tested the hypothesis that the inhibition ofthe expression ofcdk 2 kinase would result in the inhibition of neointima formation.
Our present study demonstrates increased mRNA levels of cdk 2 kinase at I d after vascular injury in association with cell cycle progression in vivo. This increase in cdk 2 kinase mRNA expression was abolished by an intraluminal administration of antisense cdk 2 kinase ODN. A single administration of antisense cdk 2 kinase ODN resulted in a significant reduction of neointima formation at 2 wk after transfection, whereas the medial thickness was not affected. The specificity of antisense ODN was supported by several observations: (a) the decrease in cdk 2 mRNA level, but not beta-actin (Fig. 1); (b) the lack of response to either sense, scrambled, or antisense thrombomodulin ODN on neointima formation (Fig. 2) ; (c) a 4-bp missense of the cdc 2 kinase antisense ODN had no effect on neointimal formation; (d) the lack of effect of cdk 2 kinase antisense ODN administered by either direct transfer or liposome-mediated transfer without HVJ particles (Fig. 3) ; (e) the inhibition of neointima formation was limited to the vascular segment transfected with antisense cdk 2 kinase ODN by the HVJ complex. Unfortunately, we were unable to completely inhibit neointima formation with the administration of cdk 2 antisense ODN alone. This may relate to the presence ofhomologues of cdk 2 kinase as well as the synergistic interaction with other cell cycle regulatory genes. Previously, we observed that cdc 2 kinase mRNA was also activated in injured arteries ( 13) . Given the multi-complex of cell cycle regulatory genes, it was logical to examine the combination of antisense cdc 2 and cdk 2 ODN. Indeed, administration of combination of antisense cdk 2 and cdc 2 kinase ODN resulted in near complete inhibition of neointima formation. Our previous work showed a marked inhibition of neointima formation by treatment with combined antisense cdc 2 kinase and proliferating cell nuclear antigen (PCNA) ODNs ( 13) . These results suggest that complete inhibition of cell cycle progression and neointima formation can only be achieved by the combined blockade of cell cycle regulatory genes at two or more steps. Indeed, our recent data using antisense cdc 2 kinase and cyclin B. ODN also showed complete inhibition only when the antisense ODNs were used together (unpublished observation). The necessity to block cell cycle regulatory genes at more than one point to achieve maximum inhibitory effects may be due to the redundancy and complexity ofthe interactions ofthe cell cycle regulatory genes. During the course of our study, Simons et al. ( 17) reported that peri-adventitial delivery ofantisense c-myb ODN via a pluronic gel inhibits neointimal formation. In addition to c-myb, our study indicates that the cell cycle regulatory genes, cdc 2 kinase and cdk 2 kinase, are also involved in promoting neointimal hyperplasia after vascular injury. Simons et al. ( 17) used 200 ,g ODN per vessel, while in our study we used 20 ,ug of ODN in liposome complex per vessel. These data suggest that the HVJ-liposome method can reduce the dosage required to achieve complete inhibition ofneointima formation as compared with the pluronic gel approach.
This study provides the first documentation that the efficiency of antisense ODN to prevent neointima formation may be limited by rapid degradation within a few days of in vivo gene transfer. 
